Ad www.AngelOne.in
FREE Account Opening + Zero AMC Fees* + MutualFund SIP1
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Ad www.AngelOne.in
Right Issue Status: Closed [15th Mar 2022 to 22nd Mar 2022]
Wockhardt right issue of Rs. 748 Cr opens for subscription from 15 Mar to 22 Mar 2022. The company issues 3 right equity shares for every 10 fully paid-up equity shares held on the record date, 9 Mar 2022. The face value of share is Rs. 5 per share and the right issue price is fixed at Rs. 225 per share. Stay updated with us to know more about the Wockhardt Rights Issue including issue size, right issue entitlement, terms of payment, and more.
The net proceeds from the right issue will be utilized towards the following objectives;
| Wockhardt Issue Details | Values |
|---|---|
| Category | RightIssue |
| Right Issue Issue Size (Shares) | 3.32 Cr |
| Right Issue Issue Size (Amount) | ₹748 Cr |
| Face Value | ₹5 Per Equity Share |
| Right Issue - Issue Price | ₹225 per share |
| Right Issue Record Date | 9th Mar 2022 |
| Right Issue Entitlement | 3 rights share for every 10 fully paid-up shares held on the record date |
| Right Issue Terms of payment | The entire amount of Rs. 225 per share is payable on the application. |
| Listing At | BSE, NSE |
| BSE Code | 532300 |
| NSE Code | WOCKPHARMA |
In this section we have covered all important dates related to Wockhardt Right Issue. Dates are updated as they are announced. The most noted dates are Right Issue start date and Right Issue end date, which one should use to participate in Right Issue.
| Right Issue Activity | Date |
|---|---|
| Right Issue Issue Open Date | 15th Mar 2022 |
| Right Issue Issue Close Date | 22nd Mar 2022 |
| Basis of Allotment Finalisation Date* | 29th Mar 2022 |
| Refunds Initiation* | 30th Mar 2022 |
| Credit of Shares to Demat Account* | 1st Apr 2022 |
| Right Issue Listing Date* | 4th Apr 2022 |
* - Tentative Dates
Zerodha Trade@20
Wockhardt Ltd is a research-based global pharmaceutical companies in India. It is engaged in the research and development, manufacturing, and distribution of pure and branded generies, vaccines, biosimilars, active pharmaceutical ingredients (APIs). It manufactures and distributes pharmaceutical products across acute therapeutic areas i.e. pain management, cough, steroids, nutrition, anti-infective, acute dermatology, and chronic therapeutic areas i.e. diabetes, neuropsychiatry, chronic pain and chronic dermatology, etc.
As of December 31, 2021, it has 12 manufacturing facilities, eight in India, 1 in UK, US, Ireland, and UAE.
Past performance and financial results of Wockhardt.
| Wockhardt Financials (₹ in Cr) | 30-Sep-2021 | 31-Mar-2021 |
|---|---|---|
| Total Assets | ₹8,009.18 | ₹7,772.69 |
| Total Income | ₹867.20 | ₹2,840.57 |
| Net Profit/Loss | ₹37.17 | ₹688.60 |
The table below is live update of Right Issue bidding details from NSE and BSE.
Wockhardt Right Issue Offer Document (Letter of Offer) >>Document
Wockhardt Right Issue Offer Document (Letter of Offer) >>Wockhardt Right Issue Red Herring Prospectus is not yet available.
Wockhardt Right Issue Online Application (Registrar & Transfer Agent) >>Online Application
Wockhardt Right Issue Online Application (Registrar & Transfer Agent) >>Wockhardt Right Issue RTA information is not yet available.
Last Updated on 2022-04-06T10:35:28+00:00
